January 31, 2017
Nativis Strengthens Board of Directors with Appointment of Sean Kell
Nativis Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that Sean Kell has been appointed to the Company’s Board of Directors, effective immediately.
Kell is currently the Chief Executive Officer of A Place for Mom, Inc., the leading senior living referral service in the U.S. and Canada; he is responsible for guiding the strategic vision, operations and overall management of the company. He previously served as the Senior Vice President and General Manager of Expedia.com, where he managed all aspects of brand marketing, e-commerce, finance, human resources, and product development. He has also held senior executive and general management roles at hotels.com and Starbucks Coffee Company, in addition to McKinsey and Company. At Starbucks, he led the office coffee, e-commerce, government and military markets. He was instrumental in implementing innovative technology, product development and marketing programs across these companies that contributed to strong growth at each business. Kell holds an MBA in Marketing and Finance from The University of Chicago and a B.S. in Electrical Engineering from The University of Southern California.
“Sean Kell brings a wealth of experience in managing and guiding innovative and disruptive companies to rapid growth and we are pleased to welcome him to Nativis’ Board of Directors,” commented Chris Rivera, Nativis’ Chief Executive Officer. “Sean has a strong track record of innovating and bringing game changing sales, marketing and commercial strategies to the table. Our novel ulRFE™ technology represents just that, a game changing opportunity to revolutionize the way we treat cancer and other serious diseases.”
Kell added, “Nativis is pioneering a unique and potentially ground breaking technology for the treatment of cancer, and I believe that my experience in developing innovative and non-traditional strategies for emerging organizations will be of great value as the company seeks to become a leader in the space. I look forward to engaging with my fellow board members and the management team to help guide the company to success.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain. Find Nativis online at nativis.com.